Singapore: Japan-based Astellas Pharma has received US FDA approval for Astagraf XL (tacrolimus extended-release capsule...
Over the last few decades India has reiterated its capabilities in providing dependable and cost effective chemistry ser...
Singapore: National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) has provi...
Singapore: Janssen Biotech has entered into a license agreement with Astellas Pharma for the worldwide development and c...
Singapore: European Commission has approved Exjade (deferasirox) for the treatment of chronic iron overload requiring ch...
Singapore: CSL Behring's novel recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP...
Singapore: Arthritis Foundation appointed Dr John Vernachio as vice president of research, effective April 15. In his ne...
Singapore: GVK Biosciences is extending its Clinical Biomarker Database (Gobiom) license to the Biomarker Qualification ...
Singapore: Japanese firm Otsuka Pharmaceutical and global firm H Lundbeck have submitted a New Drug Application (NDA) to...
Singapore: Long-term treatment with the type 2 diabetes drug metformin improves health and longevity of male mice when s...
In the last few years, biotech companies in Korea have targeted innovation in drug development and are building platform...
Singapore: German drug major Boehringer Ingelheim has planned to build a biologics plant in Shanghai, China, to offer co...
Singapore: Researchers at Singapore's Institute of Bioengineering and Nanotechnology (IBN) and California's IBM Research...
Singapore: Novartis highlighted that the results of a global phase III study showed that Afinitor (everolimus) did not e...
Singapore: Oramed Pharmaceuticals, a developer of oral drug delivery systems, submitted a pre-Investigational New Drug (...
Singapore: Australian drug delivery company, Phosphagenics, has raised $19.3 million via a placement of $16.3 million to...
Singapore, July 09, 2012: Bayer HealthCare has started to enroll patients in an international Phase II/III trial to eval...
Singapore: Asia Pacific (APAC) therapeutics market for ovarian cancer will undergo a modest rise in value, from $294.3 m...
